Linagliptin Intas

Linagliptin, the active ingredient in Linagliptin Intas, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Linagliptin Intas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels. - Monotherapy in patients inadequately controlled with diet and exercise alone: provides additional glucose‑lowering effect. - Combination therapy with metformin or other oral antidiabetics: enhances overall glycemic reduction when used together.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headed sensation. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Upper respiratory tract infection: cough or sore throat. - Skin rash: mild erythema or pruritus.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe hypersensitivity: angioedema, Stevens‑Johnson syndrome. - Hepatic injury: elevated transaminases or jaundice. - Acute renal failure: sudden decline in kidney function. - Bullous pemphigoid: blistering skin disorder. - Anaphylactic reaction: rapid onset of airway compromise.

Before initiating Linagliptin, consider patient‑specific factors and monitor appropriately.

- Renal impairment: assess kidney function and adjust therapy if needed. - Hepatic disease: use with caution in patients with liver dysfunction. - Elderly patients: monitor for hypoglycaemia when combined with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Concomitant medications: review for potential drug‑drug interactions. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with several drug classes; awareness of interaction severity helps guide therapy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Linagliptin exposure. - Insulin or sulfonylureas: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely):\n- Rifampin: may reduce Linagliptin plasma concentrations. - Diuretics and ACE inhibitors: monitor blood pressure and renal function. - Warfarin: occasional alteration of INR; check coagulation status regularly.